Problems At Valsartan Manufacturing Plant Found in New FDA Inspection

Federal regulators say they have found more problems at an Aurobindo manufacturing plant in India, which was previously linked to the manufacture and distribution of contaminated valsartan pills, resulting in massive recalls of the generic hypertension drug in the United States.

On November 6, Aurobindo issued a letter (PDF) regarding an FDA inspection at its manufacturing facility in Pashamylaram, India. The agency’s investigators found four problems at the valsartan manufacturing facility, but neither Aurobindo nor the agency has said what those problems were.

In early October, the FDA found problems with documents at another Aurobindo facility, which it deemed to be misleading or incomplete. Inspections of another Aurobindo facility are currently underway, according to the letter.

Learn More About

Valsartan Lawsuits

Side effects of recalled valsartan may increase the risk of cancer, due to an impurity discovered in certain generic versions of the hypertension drug.

Learn More About this Lawsuit SEE IF YOU QUALIFY FOR COMPENSATION

The investigations came after the agency sent a warning letter to Aurobindo in June, citing failures to meet current good manufacturing procedures (CGMPs). According to the FDA, the problems contributed to incidents of valsartan contamination.

Since summer of 2018, the FDA has announced numerous valsartan recalls and losartan recalls, due to the presence of cancer-causing impurities, including N-nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), and N-Nitroso-N-methyl-4-aminobutyric acid (NMBA).

The impurities were never found in the brand-name drug, Diovan, whose patent ran out year ago. However, the FDA and regulators from other countries have determined that the impurities are frequently found in the generic versions, due to the manufacturing processes used. Generic drugs are supposed to be virtually identical to the brand-name original.

Exposure to the recalled pills has been linked to reports of liver cancer, stomach cancer, small intestine cancer, colorectal cancer, esophageal cancer and other digestive tract cancers, and hundreds of valsartan and losartan lawsuits are now being pursued in courts nationwide against manufacturers and distributors of the pills.

A number of generic drug manufacturers now face product liability lawsuits brought by individuals diagnosed with liver cancer, kidney cancer, stomach cancer, colon cancer and other digestive tract cancers after use of the contaminated pills. However, as valsartan recall lawyers continue to review and file claims over the coming months, it is widely expected that several thousand cases will be filed nationwide.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted today)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 2 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.